Drug-induced gastrointestinal tract damages: Part 2 – sources of danger and methods of prevention


DOI: https://dx.doi.org/10.18565/therapy.2020.7.54-70

Pereverzev A.P., Ostroumova O.D.

Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia, Moscow
Current review contains information about certain groups of drugs intake of which probably could be associated with medicamentous damage of the gastrointestinal tract (GIT): proton pump inhibitors, anticoagulants, and nonsteroidal anti-inflammatory drugs, including acetylsalicylic acid in low doses. The possibility of preventing gastrointestinal tract drug damages by means of using the universal gastroenteroprotector rebamipide, which makes protective effect throughout the entire GIT, has, in addition to pharmacodynamic features, a number of important pharmacokinetic advantages and is characterized by a relatively low risk of drug-drug interactions, is considered. The results of numerous well-controlled clinical studies that have confirmed the efficacy and safety of rebamipide in different groups of patients are presented. Informing health care practitioners about the possible risks and complications of pharmacotherapy from the side of digestive system will improve patients’ safety and the effectiveness of treatment.
Keywords: adverse reactions, gastrointestinal tract, medicine remedies, rebamipide, gastropathy, enteropathy, colopathy
Read entire article

Literature


  1. Переверзев А.П., Остроумова О.Д. Лекарственно-индуцированные поражения желудочно-кишечного тракта. Часть 1 - типы и патофизиологические механизмы поражения. Терапия. 2020; 6: 171-183. [Pereverzev A.P., Ostroumova O.D. Drug-induced gastrointestinal damage: Part I – types and pathophysiological mechanisms of lesion. Therapy. 2020; 6: 171-183 (In Russ.)]. doi: https://dx.doi.org/10.18565/therapy.2020.6.171-183.

  2. Сычев Д.А., Остроумова О.Д., Кочетков А.И. с соавт. Лекарственно-индуцированные заболевания: эпидемиология и актуальность проблемы. Фарматека. 2020; 5: 77-84. [Sychev D.A., Ostroumova O.D., Kochetkov A.I. et al. Drug-induced diseases: epidemiology and urgency of the issue. Farmateka. 2020; 5: 77-84 (In Russ.)]. doi: https://dx.doi.org/10.18565/pharmateca.2020.5.77-84.

  3. Сычев Д.А., Остроумова О.Д., Переверзев А.П. с соавт. Лекарственно-индуцированные заболевания: подходы к диагностике, коррекции и профилактике. Фармаконадзор. Фарматека. 2020; 6: 113-126. [Sychev D.A., Ostroumova O.D., Pereverzev A.P. et al. Drug-induced diseases: approaches to diagnosis, correction and prevention. Pharmacovigilance. Farmateka. 2020; 6: 113-126 (In Russ.)]. doi: https://dx.doi.org/10.18565/pharmateca.2020.6.113-126.

  4. Eusebi L.H., Rabitti S., Artesiani M.L. et al. Proton pump inhibitors: Risks of long-term use. J Gastroenterol Hepatol. 2017; 32(7): 1295-302. doi: 10.1111/jgh.13737.

  5. Kwok C.S., Arthur A.K., Anibueze C.I. et al. Proton pump inhibitors and associated risk of clostridium difficile infection: A systematic review and meta-analysis of observational studies. Br J Clin Pharmacol. 2012; 73(6): 985.

  6. Bavishi C., Dupont H.L. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011; 34(11-12): 1269–81. doi: 10.1111/j.1365-2036.2011.04874.x.

  7. Clooney A.G., Bernstein C.N., Leslie W.D. et al. A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Aliment Pharmacol Ther. 2016; 43: 974–84. doi: 10.1111/apt.13568.

  8. Остроумова О.Д., Волкова Е.А., Кочетков А.И. с соавт. Профилактика желудочно-кишечных кровотечений у пациентов, получающих пероральные антикоагулянты: фокус на ингибиторы протонной помпы. Кардиоваскулярная терапия и профилактика. 2019; 5: 128-137. [Ostroumova O.D., Volkova E.A., Kochetkov A.I. et al. Prevention of gastrointestinal bleeding in patients receiving oral anticoagulants: focus on proton pump inhibitors. Kardiovaskulyarnaya terapiya i profilaktika. 2019; 5: 128-137 (In Russ.)]. doi: 10.15829/1728-8800-2019-5-128-137.

  9. Остроумова О.Д., Кочетков А.И., Переверзев А.П. с соавт. Взаимосвязь между сочетанным применением различных представителей класса ингибиторов протонной помпы с антитромбоцитарными препаратами и риском сердечно - сосудистых осложнений. Терапевтический архив. 2019; 8: 118-126. [Ostroumova O.D., Kochetkov A.I., Pereverzev A.P. et al. The relationship between the combined use of various proton pump inhibitors with antiplatelet drugs and the risk of cardiovascular complications. Terapevtichesky arkhiv. 2019; 8: 118-126 (In Russ.)]. doi: 10.26442/00403660.2019.08.000355.

  10. Ткачева О.Н., Остроумова О.Д., Котовская Ю.В. с соавт. Депрескрайбинг ингибиторов протонной помпы у пациентов пожилого и старческого возраста. Клиническая фармакология и терапия. 2019; 1: 70-74. [Tkacheva O.N., Ostroumova O.D., Kotovskaya Yu.V. et al. Deprescribing of proton pump inhibitors in the elderly. Klinicheskaya farmakologiya i terapiya. 2019; 1: 70-74 (In Russ.)].

  11. Остроумова О.Д., Переверзев А.П. Влияние ингибиторов протонной помпы на когнитивные функции и риск деменции. Consilium Medicum. 2019; 2: 31-36. [Ostroumova O.D., Pereverzev A.P. Influence of proton pump inhibitors on cognitive function and dementia risk. Consilium Medicum. 2019; 2: 31-36 (In Russ.)]. doi: 10.26442/20751753.2019.2.180171.

  12. Остроумова О.Д., Переверзев А.П., Краснов Г.С. Возможные нежелательные побочные реакции ингибиторов протонной помпы: фармакология у больных пожилого и старческого возраста. Лечебное дело. 2018; 4: 7-17. [Ostroumova O.D., Pereverzev A.P., Krasnov G.S. Possible adverse effects of proton pump inhibitors in elderly and senile patients. Lechebnoe delo. 2018; 4: 7-17 (In Russ.)].

  13. Ткачева О.Н., Маев И.В., Сычев Д.А. с соавт. Проект протокола депрескрайбинга ингибиторов протонной помпы у пациентов пожилого и старческого возраста. Статья в открытом архиве без номера. 14.05.2019. Доступ: http://rgnkc.ru/images/pdf_documets/Depreskraibing/Depreskraibing_2_0_1.pdf. (дата обращения - 09.06.2020). [Tkacheva O.N., Maev I.V., Sychev D.A. et al. Draft protocol for the deprescribing of proton pump inhibitors in elderly and senile patients. Open archive article without number. 14.05.2019. URL: http://rgnkc.ru/images/pdf_documets/Depreskraibing/Depreskraibing_2_0_1.pdf. (date of access - 09.06.2020) (In Russ.)].

  14. Hojo M., Asahara T., Nagahara A. et al. Gut microbiota composition before and after use of proton pump inhibitors. Dig Dis Sci. 2018; 63(11): 2940-49. doi:10.1007/s10620-018-5122-4.

  15. Jackson M.A., Goodrich J.K., Maxan M.E. et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016; 65(5): 749-56. doi:10.1136/gutjnl-2015-310861.

  16. Schubert A.M., Sinani H., Schloss P.D. Antibiotic-induced alterations of the murine gut microbiota and subsequent effects on colonization resistance against Clostridium difficile. MBio. 2015; 6 :e00974 10.1128/mBio.00974-15

  17. de Jager C.P.C., Wever P.C., Gemen E.F.A. et al. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. Aliment Pharmacol Ther. 2012; 36: 941–49. 10.1111/apt.12069.

  18. Jalving M., Koornstra J.J., Wesseling J. et al. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006; 24: 1341–48. doi: 10.1111/j.1365-2036.2006.03127.x.

  19. Ahn J.S., Eom C.-S., Jeon C.Y., Park S.M. Acid suppressive drugs and gastric cancer: a metaanalysis of observational studies. World J Gastroenterol. 2013; 19(16): 2560–68. doi: 10.3748/wjg.v19.i16.2560.

  20. Yang Y.X., Hennessy S., Propert K. et al. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 2007; 133: 748–54. doi: 10.1053/j.gastro.2007.06.022.

  21. Brusselaers N., Sadr-Azodi O., Engstrand L. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden. J Gastroenterol. 2020; 55: 453–61. doi: 10.1007/s00535-019-01652-z.

  22. Guo Y.S., Townsend C.M. Jr. Role of gastrointestinal hormones in pancreatic cancer. J Hepatobiliary Pancreat Surg. 2000; 7: 276–85. doi: 10.1007/s005340070049.

  23. McWilliams D.F., Watson S.A., Crosbee D.M. et al. Coexpression of gastrin and gastrin receptors (CCK-B and delta CCK-B) in gastro- intestinal tumour cell lines. Gut. 1998; 42: 795–98. doi: 10.1136/gut.42.6.795.

  24. Miyake A., Mochizuki S., Kawashima H. Characterization of cloned human cholecystokinin-B receptor as a gastrin receptor. Biochem Pharmacol. 1994; 47: 1339 –43. doi: 10.1016/0006-2952(94)90332-8.

  25. Koh T.J., Goldenring J.R., Ito S. et al. Gastrin deficiency results in altered gastric differentiation and decreased colonic proliferation in mice. Gastroenterology. 1997; 113: 1015–25. doi: 10.1016/s0016-5085(97)70199-9.

  26. Koh T.J., Dockray G.J., Varro A. et al. Overexpression of glycine- extended gastrin in transgenic mice results in increased colonic proliferation. J Clin Invest. 1999; 103: 1119 –26. doi: 10.1172/JCI4910.

  27. Wang T.C., Koh T.J., Varro A. et al. Processing and proliferative effects of human progastrin in transgenic mice. J Clin Invest. 1996; 98: 1918 –29. doi: 10.1172/JCI118993.

  28. Watson S.A., Smith A.M. Hypergastrinemia promotes adenoma progression in the APC/mouse model of familial adenomatous polyposis. Cancer Res. 2001; 61: 625–31.

  29. Seva C., Dickinson C., Yamada T. Growth-promoting effects of glycine-extended progastrin. Science. 1994; 265: 410–12. doi: 10.1126/science.8023165.

  30. 30. Singh P., Xu Z., Dai B. et al. Incomplete processing of progastrin expressed by human colon cancer cells: role of noncarboxyamidated gastrins. Am J Physiol. 1994; 266: G459–G468. doi: 10.1152/ajpgi.1994.266.3.G459.

  31. Klingensmith M.E., Neville L.J., Delpire E. et al. Gastrin-mediated effects of omeprazole on rat colon mucosa. Surgery. 1999; 125: 272–78.

  32. Sirinek K.R., Levine B.A., Moyer M.P. Pentagastrin stimulates in vitro growth of normal and malignant human colon epithelial cells. Am J Surg. 1985; 149: 35–39. doi: 10.1016/s0002-9610(85)80006-4.

  33. Watson S.A., Durrant L.G., Crosbie J.D. et al. The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin. Int J Cancer. 1989; 43: 692–96. doi: 10.1002/ijc.2910430425.

  34. Hamdeh S., Micic D., Hanauer S. Drug-induced colitis [published online ahead of print, 2020 Apr 30]. Clin Gastroenterol Hepatol. 2020; S1542-3565(20)30614-5. doi:10.1016/j.cgh.2020.04.069.

  35. Bonderup O.K., Fenger-Gron M., Wigh T. et al. Drug exposure and risk of microscopic colitis: a nationwide Danish case-control study with 5751 cases. Inflamm Bowel Dis. 2014; 20: 1702-07. doi: 10.1097/MIB.0000000000000143.

  36. Masclee G.M., Coloma P.M., Kuipers E.J. et al. Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs. Am J Gastroenterol. 2015; 110: 749-59. doi: 10.1038/ajg.2015.119.

  37. http://grls.rosminzdrav.ru (date of access – 09.06.2020).

  38. Остроумова О.Д., Волкова Е.А., Кочетков А.И. с соавт. Профилактика желудочно-кишечных кровотечений у пациентов, получающих пероральные антикоагулянты: фокус на ингибиторы протонной помпы. Кардиоваскулярная терапия и профилактика. 2019; 5: 128-137. [Ostroumova O.D., Volkova E.A., Kochetkov A.I. et al. Prevention of gastrointestinal bleeding in patients receiving oral anticoagulants: focus on proton pump inhibitors. Kardiovaskulyarnaya terapiya i profilaktika. 2019; 5: 128-137 (In Russ.)]. doi: 10.15829/1728-8800-2019-5-128-137.

  39. Переверзев А.П., Остроумова О.Д., Ткачева О.Н., Котовская Ю.В. Осложнения фармакотерапии новыми оральными антикоагулянтами, вызванные межлекарственным взаимодействием: акцент на желудочно-кишечные кровотечения. Безопасность и риск фармакотерапии. 2019; 2: 65-71. [Pereverzev A.P., Ostroumova O.D., Tkacheva O.N., Kotovskaya Yu.V. Complications of pharmacotherapy with new oral anticoagulants caused by inter-drug interactions: focus on gastrointestinal bleeding. Bezopasnost' i risk farmakoterapii. 2019; 2: 65-71 (In Russ.)]. doi: 10.30895/2312-7821-2019-7-2-65-71.

  40. Мороз Е.В., Каратеев А.Е., Крюков Е.В., Чернецов ВА. Желудочно-кишечные кровотечения при использовании новых пероральных антикоагулянтов: эпидемиология, факторы риска, лечение и профилактика. Научно-практическая ревматология. 2017; 6: 675–84. [Moroz E.V., Karateev A.E., Kryukov E.V., Chernetsov V.A. Gastrointestinal bleeding with the use of new oral anticoagulants: epidemiology, risk factors, treatment, and prevention. Nauchno-prakticheskaya revmatologiya. 2017; 6: 675–84 (In Russ.)]. doi: 10.14412/1995-4484-2017-675-684.

  41. Cheung K.S., Leung W.K. Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management. World J Gastroenterol. 2017; 23(11): 1954–63. doi: 10.3748/wjg.v23.i11.1954.

  42. Hylek E.M., Held C., Alexander J.H. et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol. 2014; 63(20): 2141–47. doi: 10.1016/j.jacc.2014.02.549.

  43. Информационный ресурс Drugs@FDA: FDA Approved Drug Products. URL: https://www.accessdata.fda.gov/scripts/cder/daf/ (date of access – 09.06.2020).

  44. Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10): 883–91. doi: 10.1056/NEJMoa1009638.

  45. Зырянов С.К., Переверзев А.П. Эффективность и безопасность применения новых пероральных антикоагулянтов для профилактики инсульта и системных эмболий у пациентов с фибрилляцией предсердий. Российский кардиологический журнал. 2017; 6: 158-163. [Zyryanov S.K., Pereverzev A.P. Efficacy and safety of the novel oral anticoagulants for prevention of stroke and systemic embolism in atrial fibrillation. Rossiysky kardiologichesky zhurnal. 2017; 6: 158-163 (In Russ.)]. doi: 10.15829/1560-4071-2017-6-158-163.

  46. Granger C.B., Alexander J.H., McMurray J.J. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981–92. doi: 10.1056/NEJMoa1107039.

  47. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation [published correction appears in N Engl J Med. 2010; 363(19): 1877]. N Engl J M ed. 2009; 361(12): 1139–51. doi: 10.1056/NEJMoa0905561.

  48. Scarpignato C., Bjarnason I. Drug-induced small bowel injury: a challenging and often forgotten clinical condition. Curr Gastroenterol Rep. 2019; 21(11): 55. doi: 10.1007/s11894-019-0726-1.

  49. Scarpignato C., Gatta L., Zullo A., Blandizzi C.; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016; 14(1): 179. doi: 10.1186/s12916-016-0718-z.

  50. Scarpignato C., Dolak W., Lanas A. et al. Rifaximin reduces the number and severity of intestinal lesions associated with use of nonsteroidal anti-inflammatory drugs in humans. Gastroenterology. 2017; 152(5): 980-82.e3. doi: 10.1053/j.gastro.2016.12.007.

  51. Altintoprak F., Dikicier E., Akyuz M. et al. A retrospective review of patients with non-traumatic spontaneous intramural hematoma. Turk J Gastroenterol. 2013; 24: 392–99. doi: 10.4318/tjg.2013.0697.

  52. Sorbello M.P., Utiyama E.M., Parreira J.G. et al. Spontaneous intramural small bowel hematoma induced by anticoagulant therapy: review and case report. Clinics (Sao Paulo). 2007; 62: 785–90. doi: 10.1590/s1807-59322007000600020.

  53. Rabinovici R., Frankel H.L., Kirton O. et al. Trauma, critical care and surgical emergencies. 584 c. Taylor & Francis, 2010. ISBN 0849398959, 9780849398957.

  54. Ольхова Е.Б., Соколов Ю.Ю., Аллахвердиев И.С. с соавт. Спонтанная интрамуральная гематома двенадцатиперстной кишки у ребенка (клинический пример). Доступ: http://radp.ru/db/20165/53-59.pdf (дата обращения – 09.06.2020). [Olkhova E.B., Sokolov Yu.Yu., Allakhverdiev I.S. et al. Spontaneous intramural hematoma of the duodenum in a child (clinical case). URL: http://radp.ru/db/20165/53-59.pdf (date of access – 09.06.2020) (In Russ.)].

  55. Ruszniewskiy P., Sou C. et al. NSAIDs intakes is a risk factor for gastroesophageal reflux. Gut. 2006; 55 (Suppl. V): A267.

  56. Каратеев А.Е., Успенский Ю.П., Пахомова И.Г., Насонов Е.Л. Прием НПВП и патология пищевода: связь с основными симптомами гастроэзофагеальной рефлюксной болезни (ГЭРБ), частота развития и факторы риска эрозивного эзофагита. Экспериментальная и клиническая гастроэнтерология. 2008; 3:11–16. [Karateev A.E., Uspensky Yu.P., Pakhomova I.G., Nasonov E.L. NSAID intake and esophageal pathology: relationship with the main symptoms of gastroesophageal reflux disease (GERD), incidence and risk factors for erosive esophagitis. Eksperimental'naya i klinicheskaya gastroenterologiya. 2008; 3:11–16 (In Russ.)].

  57. Wallace J.L. Mechanisms, prevention and clinical implications of non- steroidal anti-inflammatory drug-enteropathy. World J Gastroenterol. 2013; 19(12): 1861-76. doi: 10.3748/wjg.v19.i12.1861.

  58. Silverstein F.E., Graham D.Y., Senior J.R. et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995; 123: 241–49. doi: 10.7326/0003-4819-123-4-199508150-00001.

  59. Laine L., Connors L.G., Reicin A. et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology. 2003; 124: 288–92. doi: 10.1053/gast.2003.50054.

  60. Graham D.Y., Opekun A.R., Willingham F.F. et al. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005; 3: 55–59. doi: 10.1016/s1542-3565(04)00603-2.

  61. Maiden L., Thjodleifsson B., Theodors A. et al. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005; 128: 1172–78. doi: 10.1053/j.gastro.2005.03.020.

  62. Smecuol E., Sanchez M., Suarez A. et al. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment. Clin Gastroenterol Hepatol. 2009; 7(5): 524-29. doi: 10.1016/j.cgh.2008.12.019.

  63. Fortun P.J., Hawkey C.J. Nonsteroidal antiinflammatory drugs and the small intestine. Curr Opin Gastroenterol. 2007; 23(2): 134-41. doi: 10.1097/MOG.0b013e328020045a.

  64. Utzeri E., Usai P.. Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease. World J Gastroenterol. 2017; 23(22): 3954-63. doi: 10.3748/wjg.v2 3.i22.3954.

  65. Свистунов А.А., Осадчук М.А., Киреева Н.В. с соавт. НПВП-индуцированная энтеропатия: современное состояние проблемы. Терапевтический архив. 2018; 8: 95-100. [Svistunov A.A., Osadchuk M.A., Kireeva N.V. et al. NSAID-induced enteropathy: the current state of the problem. Terapevtichesky arkhiv. 2018; 8: 95-100 (In Russ.)]. doi: 10.26442/terarkh201890895-100.

  66. Ивашкин В.Т., Шептулин А.А., Маев И.В. с соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению эрозивно- язвенных поражений желудка и двенадцатиперстной кишки, вызванных нестероидными противовоспалительными препаратами. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014; 6: 89-94. [Ivashkin V.T., Sheptulin A.A., Maev I.V. et al. Russian Gastroenterological Association clinical guidelines on diagnostics and treatment of NSAID-associated erosive and ulcerative lesions of the stomach and duodenum. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. 2014; 6: 89-94 (in Russ.)].

  67. Лазебник Л.Б., Голованова Е.В., Алексеенко С.А. с соавт. Рекомендации по профилактике и лечению эзофаго-гастро-энтеро-колопатий, индуцированных нестероидными противовоспалительными препаратами (НПВП). Доступ: https://www.rnmot.ru/public/uploads/RNMOT/clinical/2018/КЛАССИФИКАЦИЯ%20Л.ЛАЗЕБНИК.%20Г.БЕЛОВА%20ДЛЯ%20УТВЕРЖДЕНИЯ%20НА%20КОНГРЕССЕ.pdf (дата обращения – 09.06.2020). [Lazebnik L.B., Golovanova E.V., Alekseenko S.A. et al. Recommendations for the prevention and treatment of esophago-gastro-enterocolopathies induced by nonsteroidal anti-inflammatory drugs (NSAIDs). URL: https://www.rnmot.ru/public/uploads/RNMOT/clinical/2018/КЛАССИФИКАЦИЯ%20Л.ЛАЗЕБНИК.%20Г.БЕЛОВА%20ДЛЯ%20УТВЕРЖДЕНИЯ%20НА%20КОНГРЕССЕ.pdf (date of access – 09.06.2020) (In Russ.)].

  68. Elliott S.N., Buret A., McKnight W. et al. Bacteria rapidly colonize and modulate healing of gastric ulcers in rats. Am J Physiol. 1998; 275(3 Pt 1): G425-G432. doi: 10.1152/ajpgi.1998.275.3.G425.

  69. Watanabe T, Sugimori S, Kameda N, et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostal: a pilot study. Clin Gastroenterol Hepatol. 2008 Nov;6(11):1279-1282. doi: 10.1016/j.cgh.2008.06.02

  70. Scheiman J.M, Yeomans N.D., Talley N.J. et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006; 101(4): 701-710. doi: 10.1111/j.1572-0241.2006.00499.x.

  71. Zhao Y., Encinosa W. Hospitalizations for Gastrointestinal Bleeding in 1998 and 2006: Statistical Brief #65. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb-2008 Dec.

  72. Blackler R., Syer S., Bolla M. et al. Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS One. 2012; 7(4): e35196. doi: 10.1371/journal.pone.0035196.

  73. Satoh H., Amagase K., Takeuchi K. Exacerbation of nonsteroidal antiinflammatory drug-induced small intestinal lesions by antisecretory drugs in rats: the role of intestinal motility. J Pharmacol Exp Ther. 2012; 343(2): 270-77. doi: 10.1124/jpet.112.197475.

  74. Wallace J.L. NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies. Br J Pharmacol. 2012; 165(1): 67-74. doi: 10.1111/j.1476-5381.2011.01509.x.

  75. Tanaka A., Hase S., Miyazawa T., Takeuchi K. Up-regulation of cy- clooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther. 2002; 300(3): 754-61. doi: 10.1124/jpet.300.3.754.

  76. Lee I.S., Cho Y.K. Initial steps to prevent nonsteroidal anti-inflammatory drug- or aspirin-induced enteropathy: long-term outcome data. Gut Liver. 2015; 9(6): 697–98. doi: 10.5009/gnl15287.

  77. Watanabe T., Sugimori S., Kameda N. et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol. 2008; 6: 1279–82. doi: 10.1016/j.cgh.2008.06.021.

  78. Kuramoto T., Umegaki E., Nouda S. et al. Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study. BMC Gastroenterol. 2013; 13: 85. doi: 10.1186/1471-230X-13-85.

  79. Endo H., Sakai E., Taniguchi L. et al. Risk factors for small-bowel mucosal breaks in chronic low-dose aspirin users: data from a prospective multicenter capsule endoscopy registry. Gastrointest Endosc. 2014; 80: 826–34. doi: 10.1016/j.gie.2014.03.024.

  80. Lanas A., Sostres C. PPI therapy: the small bowel, low-dose aspirin and PPIs. Should we be concerned? Nat Rev Gastroenterol Hepatol. 2014; 11: 458–60. doi: 10.1038/nrgastro.2014.120.

  81. Sostres C., Gargallo C J., Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res. Ther. 2013; 15 (Suppl. 3): S3. doi: 10.1186/ar4175.

  82. Boelsterli U.A., Redinbo M.R., Saitta K.S. Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies. Toxicol Sci. 2013; 131(2): 654-67. doi: 10.1093/toxsci/kfs310.

  83. Chan S.S., Luben R., Bergmann M.M. et al. Aspirin in the aetiology of Crohn’s disease and ulcerative colitis: a European prospective cohort study. Aliment Pharmacol Ther. 2011; 34: 649–55. doi: 10.1111/j.1365-2036.2011.04784.x.

  84. Evans J.M., McMahon A.D., Murray F.E. et al. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut. 1997; 40(5): 619-22. doi: 10.1136/gut.40.5.619.

  85. Dubeau M.F., Iacucci M., Beck P.L. et al. Drug-induced inflammatory bowel disease and IBD-like conditions. Inflamm Bowel Dis. 2013; 19(2): 445456. doi:10.1002/ibd.2299053.

  86. Sandborn W.J., Stenson W.F., Brynskov J. et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006; 4: 203–11. doi: 10.1016/j.cgh.2005.12.002.

  87. Marginean E.C. The ever-changing landscape of drug-induced injury of the lower gastrointestinal tract. Arch Pathol Lab Med. 2016; 140(8): 748-58. doi: 10.5858/arpa.2015-0451-RA.

  88. Duzenli T. Severe ischemic colitis probably related to diclofenac. Gastroenterol Nurs. 2019; 42(3): 297-98. doi: 10.1097/SGA.0000000000000445.

  89. Bielefeldt K. Ischemic colitis as a complication of medication use: an analysis of the federal adverse event reporting system. Dig Dis Sci. 2016; 61(9): 2655-65. doi:10.1007/s10620-016-4162-x.

  90. Milman N., Kraag G. NSAID-induced collagenous colitis. J Rheumatol. 2010; 37(11): 2432-33. doi: 10.3899/jrheum.100573.

  91. Chande N., Driman D.K., Reynolds R.P.E. Collagenous colitis and lymphocytic colitis: patient characteristics and clinical presentation. Scand J Gastroenterol. 2005; 40(3): 343-47. doi: 10.1080/00365520510011623.

  92. Kakar S., Pardi D.S., Burgart L.J. Colonic ulcers accompanying collagenous colitis: implication of nonsteroidal anti-inflammatory drugs. Am J Gastroenterol. 2003; 98(8): 1834-37. doi: 10.1111/j.1572-0241.2003.07579.x.

  93. Bielsa-Fernandez M.V., Tamayo-de la Cuesta J.L., Lizarraga-Lopez J. et al. Consenso mexicano sobre diagnóstico, prevencion y tratamiento de la gastropatía y enteropatía por antiinflamatorios no esteroideos. Revista de Gastroenterología de Mexico. 2020. doi: 10.1016/j.rgmx.2019.11.003.

  94. Oh J.H., Kwon J.G., Jung H.K. et al. Clinical practice guidelines for functional dyspepsia in Korea. J Neurogastroenterol Motil. 2020; 26(1): 29-50. doi: 10.5056/jnm19209.

  95. Surdea-Blaga T., Bancila I., Dobru D. et al. Mucosal Protective compounds in the treatment of gastroesophageal reflux disease. A position paper based on evidence of the Romanian Society of Neurogastroenterology. J Gastrointestin Liver Dis. 2016; 25(4): 537-46. doi: 10.15403/jgld.2014.1121.254.dea.

  96. Воробьева Н.М., Ткачева О.Н. Повышенная проницаемость кишечной стенки и ее роль в возникновении сердечно-сосудистых заболеваний. Фарматека. 2020; 3: 122–128. [Vorobyeva N.M., Tkacheva O.N. Increased intestinal permeability and its role in the development of cardiovascular diseases. Farmateka. 2020; 3: 122–128 (In Russ.)]. doi: https://dx.doi.org/10.18565/pharmateca.2020.3.122-128.

  97. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. с соавт. Рациональное использование нестероидных противовоспалительных препаратов. клинические рекомендации. Научно-практическая ревматология. 2018; 56: 1-29. [Karateev A.E., Nasonov E.L., Ivashkin V.T. et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-prakticheskaya revmatologiya. 2018; 56 (Suppl. 1): 1–29 (In Russ.)]. doi: 10.14412/1995-4484-2018-1-29.

  98. Оганов Р.Г., Симаненков В.И., Бакулин И.Г. с соавт. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019; 1: 5-66. [Oganov R.G., Simanenkov V.I., Bakulin I.G. et al. Comorbidities in clinical practice. algorithms for diagnostics and treatment. Kardiovaskulyarnaya terapiya i profilaktika. 2019; 1: 5-66 (In Russ.)]. doi: 10.15829/1728-8800-2019-1-5-66.

  99. https://grls.rosminzdrav.ru (date of access – 09.06.2020).

  100. Arakawa T., Kobayashi K., Yoshikawa T., Tarnawski A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Digestive Diseases and Sciences. 1998; 43 (9 Suppl): 5S–13S.

  101. Казюлин А.Н., Гончаренко А.Ю., Маев И.В. Использование ребамипида в качестве гастропротективного и противовоспалительного препарата при НПВП-гастропатиях. Лечебное дело. 2016; 3: 50-59. [Kazyulin A.N., Goncharenko Yu., Maev V. Rebamipide for NSAID-induced gastropathy. Lechebnoe delo. 2016; 3: 50-59 (In Russ.)].

  102. Genta R.M. Review article: the role of rebamipide in the management of inflammatory disease of the gastrointestinal tract. Aliment Pharmacol Ther. 2003; 18(1): 8–13. doi: 10.1046/j.1365-2036.18.s1.5.x.

  103. Du Y., Li Z., Zhan X. et al. Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: a randomized sucralfate-controlled multicenter trial in China-STARS study. Dig Dis Sci. 2008; 53(11): 2886–95. doi: 10.1007/s10620-007-0180-z.

  104. Han X., Jiang K., Wang B. et al. Effect of rebamipide on the premalignant progression of chronic gastritis: a randomized controlled study. Clin Drug Investig. 2015; 35(10): 665–73. doi: 10.1007/s40261-015-0329-z.

  105. Tarnawski A.S., Chai J., Pai R., Chiou S.K. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004; 49(2): 202–09. doi: 10.1023/b:ddas.0000017439.60943.5c.

  106. Драпкина О.М., Корнеева О.Н. Поражения тонкой кишки при применении нестероидных противовоспалительных препаратов и антитромбоцитарной терапии. Подходы к профилактике и лечению. Терапевтический архив. 2016; 12: 133-139. [Drapkina O.M., Korneeva O.N. Small bowel injuries due to nonsteroidal anti-inflammatory drugs and antiplatelet therapy. approaches to prevention and treatment. Terapevtichesky arkhiv. 2016; 12: 133-139 (In Russ.)]. doi: 10.17116/terarkh20168812133-139.

  107. Suzuki T., Yoshida N., Nakabe N. et al. Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci. 2008; 106(3): 469-77. doi: 10.1254/jphs.fp0071422.

  108. Tarnawski A.S., Chai J., Pai R., Chiou S.K. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004; 49(2): 202‐09. doi:10.1023/b:ddas.0000017439.60943.5c.

  109. Ивашкин В.Т., Маев И.В., Лапина Т.Л. с соавт. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018; 1: 55-70. [Ivashkin V.T., Mayev I.V., Lapina T.L. et al. Diagnostics and treatment of Helicobacter Pylori infection in adults: clinical guidelines of the Russian Gastroenterological Association. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii. 2018; 1: 55-70 (In Russ.)]. doi:10.22416/1382-4376- 2018-28-1-55-70.

  110. Naito Y., Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010; 4(3): 261–70. doi:10.1586/egh.10.25.

  111. Koyama N., Sasabe H., Miyamoto G. Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver. Xenobiotica 2002; 32(7): 573–86. doi: 10.1080/00498250210130591.

  112. Kim H.K., Kim J.I., Kim J.K. et al. Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. Dig Dis Sci. 2007; 52(8): 1776–82. doi: 10.1007/s10620-006-9367-y.

  113. Ono S., Kato M., Imai A. et al. Preliminary trial of rebamipide for prevention of low-dose aspirin-induced gastric injury in healthy subjects: a randomized, double-blind, placebo-controlled, cross-over study. J Clin Biochem Nutr. 2009; 45(2): 248–53. doi: 10.3164/jcbn.09-24.

  114. Naito Y., Yoshikawa T., Iinuma S. et al. Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study. Dig Dis Sci. 1998; 43(9 Suppl): 83S-89S.

  115. Naito Y., Iinuma S., Yagi N. et al. Prevention of indomethacin-induced gastric mucosal injury in Helicobacter pylori-negative healthy volunteers: a comparison study rebamipide vs famotidine. J Clin Biochem Nutr. 2008; 43(1): 34-40. doi: 10.3164/jcbn.2008041.

  116. Hasegawa M., Horiki N., Tanaka K. et al. The efficacy of rebamipide add-on therapy in arthritic patients with COX-2 selective inhibitor-related gastrointestinal events: a prospective, randomized, open-label blinded-endpoint pilot study by the GLORIA study group. Mod Rheumatol. 2013; 23(6): 1172-78. doi: 10.1007/s10165-012-0819-2.

  117. Park S.H., Cho C.S., Lee O.Y. et al. Comparison of prevention of NSAID-induced gastrointestinal complications by rebamipide and misoprostol: a randomized, multicenter, controlled trial-STORM Study. J Clin Biochem Nutr. 2007; 40(2): 148-55. doi:10.3164/jcbn.40.148.

  118. Kim J.H., Park S.H., Cho C.S. et al. Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity. Gut Liver. 2014; 8(4): 371-79. doi:10.5009/gnl.2014.8.4.371.

  119. Tozawa K., Oshima T., Okugawa T. et al. A randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel. Dig Dis Sci. 2014; 59(8): 1885-90. doi: 10.1007/s10620-014-3108-4.

  120. Pittayanon R., Piyachaturawat P., Rerknimitr R. et al. Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: a randomized, double-blind placebo-controlled trial. J Gastroenterol Hepatol. 2019; 34(9): 1517-22. doi:10.1111/jgh.14671.

  121. Yamashita T., Watanabe E., Ikeda T. et al. Observational study of the effects of dabigatran on gastrointestinal symptoms in patients with non-valvular atrial fibrillation. Journal of Arrhythmia. 2014; 30(6): 478–84. doi:10.1016/j.joa.2014.02.011.

  122. Seo G.H., Lee H. Chemopreventive effect of rebamipide against gastric cancer in patients who undergo endoscopic resection for early gastric neoplasms: a nationwide claims study. Digestion. 2019; 100(4): 221-28. doi: 10.1159/000495288.

  123. Звяглова М.Ю., Князев О.В., Парфенов А.И. Фармакологический и клинический профиль ребамипида: новые терапевтические мишени. Терапевтический архив. 2020; 2: 104–111. [Zvyaglova M.Yu., Knyazev O.V., Parfenov A.I. Pharmacological and clinical feature of rebamipide: new therapeutic targets. Terapevtichesky arkhiv. 2020; 2: 104–111 (In Russ.)]. doi: 10.26442/00403660.2020.02.000569.

  124. Zhang S., Qing Q., Bai Y. et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. 2013; 58(7): 1991-2000. doi: 10.1007/s10620-013-2606-0.

  125. Niwa Y., Nakamura M., Ohmiya N. et al. Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. J Gastroenterol. 2008; 43(4): 270-76. doi: 10.1007/s00535-007-2155-4.

  126. Kurokawa S., Katsuki S., Fujita T. et al. A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury [published correction appears in J Gastroenterol. 2014; 49(2): 373]. J Gastroenterol. 2014; 49(2): 239-44. doi: 10.1007/s00535-013-0805-2.

  127. Watanabe T., Takeuchi T., Handa O. et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-to-severe small intestinal damage. PLoS One. 2015; 10(4): e0122330. doi: 10.1371/journal.pone.0122330.

  128. Lai Y., Zhong W., Yu T. et al. Rebamipide promotes the regeneration of aspirin-induced small-intestine mucosal injury through accumulation of β-catenin. PLoS One. 2015; 10(7): e0132031. doi:10.1371/journal.pone.0132031.

  129. Nishida U., Kato M., Nishida M. et al. Evaluation of small bowel blood flow in healthy subjects receiving low-dose aspirin. World J Gastroenterol. 2011; 17(2): 226-30. doi: 10.3748/wjg.v17.i2.226.

  130. Takagi T., Naito Y., Uchiyama K. et al. Rebamipide promotes healing of colonic ulceration through enhanced epithelial restitution. World J Gastroenterol. 2011; 17(33): 3802-09. doi: 10.3748/wjg.v17.i33.3802.

  131. Mizukami K., Murakami K., Hirashita Y. et al. Efficacy of rebamipide for low-dose aspirin-related gastrointestinal symptoms. J Clin Biochem Nutr. 2012; 51(3): 216-20. doi: 10.3164/jcbn.12-27.

  132. Zhang S., Qing Q., Bai Y. et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. 2013; 58(7): 1991-2000. doi: 10.1007/s10620-013-2606-0.


About the Autors

Anton P. Pereverzev, PhD, associate professor of the Department of therapy and polymorbid pathology of Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia. Address: 125993, Moscow, 2/1 build 1 Barrikadnaya Str. Tel.: +7 (916) 538-87-81. E-mail: acchirurg@mail.ru. ORCID: 0000-0001-7168-3636. ESPIN: 4842-3770
Olga D. Ostoumova, MD, professor, head of the Department of therapy and polymorbid pathology of Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia. Address: 125993, Moscow, 2/1 build 1 Barrikadnaya Str. Tel.: +7 (903) 169-68-28. E-mail: ostroumova.olga@mail.ru. ORCID: 0000-0002-0795-8225. ESPIN: 3910-6585

Back to Content

Бионика Медиа